摘要 |
The object of the present invention is to provide a therapeutic agent which increases cancellous bone mass without the risk of PTH-induced loss of cortical bone in treating osteopenia. When PTH is administered while inhibiting in vivo effects of osteopontin, it is possible to increase not only cancellous bone mass, but also cortical bone mass.
|